Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 3/20 | 0.46 |
| ▸ | CMA1 | P23946 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395562 | 0.89 | KIF11 (0.66) | KIF11KDM4EMEN1LMNAGAA | |
| SCHEMBL396156 | 0.87 | DDX3X (0.59) | TDP2CRBNFABP7FABP5SMYD3 | |
| SCHEMBL16208502 | 0.79 | KIF11 (0.67) | KIF11CA9CRBNDDB1 | |
| SCHEMBL25430331 | 0.79 | CA9 (0.44) | KIF11MAPTTDP1TDP2AHR | |
| SCHEMBL30623134 | 0.79 | CA9 (0.44) | KIF11MAPTTDP1TDP2AHR | |
| SCHEMBL30468520 | 0.78 | CA9 (0.70) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL398137 | 0.78 | CA9 (0.70) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL10713146 | 0.78 | TDP2 (0.69) | TDP2AHRCMA1CA9EIF2AK2 | |
| Hydrochloric Acid SCHEMBL9833199 | 0.76 | CA9 (0.68) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL394638 | 0.76 | AHR (0.45) | KIF11KDM4EMEN1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |
| CN-101056632-B | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2011-12-07 | — | — | CN | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2010-07-01 | — | — | US | disclosed |
| EP-2102190-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-09-23 | — | — | EP | disclosed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073480-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2008-06-19 | — | — | WO | disclosed |
| CN-101056632-A | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2007-10-17 | — | — | CN | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | KIF11 1787/4885KDM4E 1774/4885MEN1 1484/4885 |
| US-20100168182-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NTRK2, PDGFRB, PDGFRA | KIF11 1787/4885KDM4E 1999/4885MEN1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.